[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336900-105":59,"doc-detail-336900-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","egfr-mutation-testing-treatment-and-survival-in-stage-iiii-non-small-cell-lung-cancer-cancerlinq-discovery-database-retrospective-analysis","EGFR mutation testing, treatment and survival in stage I–III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis","","Aim: Describe real-world biomarker testing, treatment, and survival in stage IA–IIIC non-small cell lung cancer (NSCLC). Methods: Screened electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA–IIIC NSCLC diagnosed between 2014 and 2018, identifying 14,452 records for analysis. Results: Among 3121 patients who had EGFR testing, 493 were EGFR-mutation positive; among 974 treated with surgical resection, 513 received adjuvant therapy. Approximately one quarter received targeted adjuvant therapy. Conclusion: About one fifth underwent EGFR testing; biomarker testing supports optimal outcomes for stage I–III NSCLC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-mutation-testing-treatment-and-survival-in-stage-iiii-non-small-cell-lung-cancer-cancerlinq-discovery-database-retrospective-analysis/336900/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-mutation-testing-treatment-and-survival-in-stage-iiii-non-small-cell-lung-cancer-cancerlinq-discovery-database-retrospective-analysis/336900.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding EGFR in stage I–III NSCLC?","Question",{"text":112,"@type":113},"The study aimed to describe real-world EGFR biomarker testing, treatment patterns, and survival outcomes in stage IA–IIIC NSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected for the analysis?",{"text":117,"@type":113},"Researchers screened electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA–IIIC NSCLC diagnosed between 2014 and 2018, then analyzed a curated cohort of 14,452 records.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about EGFR testing and positive mutation rates?",{"text":121,"@type":113},"Among patients who received EGFR testing (3121, 21.6%), 493 (15.8%) were EGFR-mutation positive. Of patients undergoing surgical resection (974), 513 (52.7%) received adjuvant therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336900,1790149486,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","FUTURE ONCOLOGY  \n2024, VOL. 20, NO. 28, 2083–2096  \n[https://doi.org/10.1080/14796694.2024.2347826](https://doi.org/10.1080/14796694.2024.2347826)  \nRESEARCH ARTICLE     \nEGFR mutation testing, treatment and survival in stage I–III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis  \nBharathi Muthusamy* , a, Mehmet Berktasb, Jingyi Lic, Darren S Thomasb, Ping Sunb, Aliki Taylor‡,b and Nathan APennella  \na Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA; b Global Oncology Outcome Research, AstraZeneca, Cambridge, UK; c Global Medical Aﬀairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD 20878, USA  \nABSTRACT  \nAim: To describe real-world biomarker testing, treatment and survival in stage IA–IIIC non-small cell lung cancer (NSCLC) .  \nMethods: Electronic records of USA-based patients in the CancerLinQ Discovery􀀂R database with stage IA–IIIC NSCLC (diagnosed between 2014 and 2018) were screened; a curated cohort of 14,452 records was identified for further analysis.  \nResults: Of 3121 (21.6%) patients who had EGFR testing, 493 (15.8%) were EGFR-mutation positive. Of 974 patients who underwent surgical resection, 513 (52.7%) received adjuvant therapy. A quarter of patients with EGFR-mutation positive NSCLC received targeted adjuvant therapy.  \nConclusion: Approximately a fifth of patients underwent EGFR testing; biomarker testing is important to ensure optimal outcomes for patients with stage I–III NSCLC.  \nPLAIN LANGUAGE SUMMARY  \nA study investigating how many patients with early-stage non-small cell lung cancer (NSCLC) had mutations in a protein called EGFR and which treatments they received in routine clinical practice: The treatment recommended by medical experts for stage IA–IIIA non-small cell lung cancer (NSCLC) is surgical removal of the growth (tumor) . Patients with stage II or III, and some with stage IB disease, are recommended to receive treatment with medications such as chemotherapy or oral cancer treatments after surgery (adjuvant treatment). In some lung cancers, there are mutations in a protein called EGFR. Osimertinib, a drug that blocks the activity of mutated EGFR on cancer cells, reducing their growth and spread, is recommended as an adjuvant treatment for patients with EGFR-mutated, stage IB–IIIA NSCLC. This study aimed to understand how many patients with stage I–III NSCLC have tumors with EGFR mutations, and which treatments patients received in everyday clinical practice, before new medicines such as osimertinib (that treat EGFR-mutated NSCLC) were recommended. We looked at anonymous data from 14,452 patients with stage I–III NSCLC treated at cancer clinics in the USA between 2014 and 2018. We found that 3121 (21.6%) patients had an EGFR mutation test and 493 (15.8%) had EGFR-mutation positive NSCLC. Of patients who had surgery to remove the tumor, 55% received adjuvant therapy (treatment after surgery) . It is important to perform EGFR mutation testing in patients with stage IB–IIIA NSCLC so that patients with EGFRmutation positive NSCLC can receive appropriate treatment.  \nARTICLE HISTORY  \nReceived 6 June 2023 Accepted 23 April 2024  \nKEYWORDS  \nbiomarker testing; EGFR mutation; epidermal growth factor receptor; EGFR; non-small cell lung cancer; real-world data; stage I–III; surgery; treatment  \n1. Introduction  \nLung cancer is the third most common cancer type in the USA, with non-small cell lung cancer (NSCLC) accounting for approximately 80% of lung cancer diagnoses [1] . Whereas the majority of patients with NSCLC present with advanced and/or metastatic disease (stage IV), approximately 40% are diagnosed in stage I–III in the USA [2] . Survival rates vary considerably by stage of  \ndiagnosis. Five-year survival is 70–85% for stage IA and 60–75% for stage IB versus 30–45% for stage IIIA, while patients with stage IV NSCLC rarely achieve long-term survival [3–5] . As a result, early diagnosis and treatment of NSCLC is cri","cbCaiqehpNlxWMmo","https://ap.wps.com/l/cbCaiqehpNlxWMmo","pdf",1536348,14,"English","# Introduction\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"What was the study aim regarding EGFR in stage I–III NSCLC?\",\"answer\":\"The study aimed to describe real-world EGFR biomarker testing, treatment patterns, and survival outcomes in stage IA–IIIC NSCLC.\"},{\"question\":\"How were patients selected for the analysis?\",\"answer\":\"Researchers screened electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA–IIIC NSCLC diagnosed between 2014 and 2018, then analyzed a curated cohort of 14,452 records.\"},{\"question\":\"What did the study find about EGFR testing and positive mutation rates?\",\"answer\":\"Among patients who received EGFR testing (3121, 21.6%), 493 (15.8%) were EGFR-mutation positive. Of patients undergoing surgical resection (974), 513 (52.7%) received adjuvant therapy.\"}]","EGFR mutation testing, treatment and survival in stage I–III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis | PDF",1790017012,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25192dbbf2442cbf16116e0d864cb8ca.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/454af5710f1e2063ed58e677bcf84513.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/127481b21b9d87edc4bb15d50eafb5de.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98d2e24aca961f1a248b1d54012db028.webp",980,1268]